Michlewska Sylwia, Maroto Marta, Hołota Marcin, Kubczak Malgorzata, Sanz Del Olmo Natalia, Ortega Paula, Shcharbin Dzmitry, de la Mata Francisco Javier, Bryszewska Maria, Ionov Maksim
Laboratory of Microscopic Imaging & Specialized Biological Techniques. Faculty of Biology & Environmental Protection. University of Lodz, Banacha12/16, Lodz 90-237, Poland.
Universidad de Alcalá. Department of Organic and Inorganic Chemistry, and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid, Spain.
Dalton Trans. 2021 Jul 13;50(27):9500-9511. doi: 10.1039/d1dt01388b.
Carbosilane ruthenium(ii) dendrimers have been complexed with conventional anti-cancer drugs. Due to its features, the presence of ruthenium within a dendrimer structure improves the anti-cancer properties of nanocomplexes containing 5-flurouracyl, methotrexate and doxorubicin. These dendrimers could be promising carriers of anti-cancer medicines. Ruthenium dendrimers that are positively charged can also enhance the cytotoxicity to cancer cells; moreover, they can form stable complexes with drugs. Results indicate that ruthenium dendrimers combined with doxorubicin and methotrexate significantly reduced the viability of leukaemia 1301 and HL-60 cancer cells.
碳硅烷钌（II）树枝状大分子已与传统抗癌药物络合。由于其特性，树枝状大分子结构中钌的存在提高了含有5-氟尿嘧啶、甲氨蝶呤和阿霉素的纳米复合物的抗癌性能。这些树枝状大分子可能是有前途的抗癌药物载体。带正电荷的钌树枝状大分子还可以增强对癌细胞的细胞毒性；此外，它们可以与药物形成稳定的复合物。结果表明，钌树枝状大分子与阿霉素和甲氨蝶呤联合使用可显著降低白血病1301和HL-60癌细胞的活力。
